Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials.

NVO's Q2 earnings beat but revenues miss estimates as Wegovy and Ozempic face U.S. setbacks and rising competition.

CNBC's Brandon Gomez and Angelica Peebles join 'Power Lunch' to break down the biggest headlines in the pharmaceutical space.

In this video, the humorous side of dining at Olive Garden is explored through the lens of the waitstaff. It showcases the ...

This summary covers recent developments in health, including Novo Nordisk filing lawsuits against semaglutide compounders, ...

Novo Nordisk faces a critical phase with its obesity drug Wegovy as it confronts competition from Eli Lilly and potential job ...

Advanced Micro Devices ( AMD -1.39%) upped its Q3 revenue guidance to $8.4 billion to $9 billion, and Q2's $7.7 billion ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some success ...

Pfizer CEO says drugmakers ‘are all ready to roll up their sleeves and execute’ as president demands more direct-to-consumer ...

"We're buyers of dips": Mike Wilson, strategist at Morgan Stanley ( MS 1.58%), said he expects a "modest pullback in the ...

At their peak last year, one share in the company Novo Nordisk cost $142; now, they can be bought for under $50.

Measures intended to punish elite universities are inflicting collateral damage on the nation’s two-year colleges, which ...